Bicycle Therapeutics' Latest Trial Results Raise Questions -- Market Talk

Dow Jones

Dec 14, 2024

1319 ET - Bicycle Therapeutics takes a beating after sharing its latest cancer treatment trial results. B. Riley analyst Kalpit Patel says the results for Bicycle's zelenectide pevedotin therapy in conjunction with Merck's pembrolizumab to treat bladder cancer included "a significant proportion of unconfirmed responses," and while the data are early, he says the effectiveness appears to be "somewhat underwhelming," when compared to the established combination of Astellas' Padcev + pembro. Patel also says results for Bicycle's breast and lung cancer treatment relied on a post-hoc analysis, which carries "an inherent risk of data mining." The analyst cautions that outcomes from such analyses often fail to replicate in later studies. Bicycle Therapeutics plunges 30% to $14.07. (katherine.hamilton@wsj.com)

(END) Dow Jones Newswires

December 13, 2024 13:19 ET (18:19 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2491309899"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2491309899\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2491309899?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-14 02:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491309899","market":"sh","top_or_hot":-1,"title":"Bicycle Therapeutics' Latest Trial Results Raise Questions -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1319 ET - Bicycle <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> takes a beating after sharing its latest cancer treatment trial results. B. Riley analyst Kalpit Patel says the results for Bicycle's zelenectide pevedotin therapy in conjunction with Merck's pembrolizumab to treat bladder cancer included \"a significant proportion of unconfirmed responses,\" and while the data are early, he says the effectiveness appears to be \"somewhat underwhelming,\" when compared to the established combination of Astellas' Padcev + pembro. Patel also says results for Bicycle's breast and lung cancer treatment relied on a post-hoc analysis, which carries \"an inherent risk of data mining.\" The analyst cautions that outcomes from such analyses often fail to replicate in later studies. Bicycle Therapeutics plunges 30% to $14.07.  (katherine.hamilton@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 13, 2024 13:19 ET (18:19 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bicycle Therapeutics' Latest Trial Results Raise Questions -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBicycle Therapeutics' Latest Trial Results Raise Questions -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-14 02:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1319 ET - Bicycle <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> takes a beating after sharing its latest cancer treatment trial results. B. Riley analyst Kalpit Patel says the results for Bicycle's zelenectide pevedotin therapy in conjunction with Merck's pembrolizumab to treat bladder cancer included \"a significant proportion of unconfirmed responses,\" and while the data are early, he says the effectiveness appears to be \"somewhat underwhelming,\" when compared to the established combination of Astellas' Padcev + pembro. Patel also says results for Bicycle's breast and lung cancer treatment relied on a post-hoc analysis, which carries \"an inherent risk of data mining.\" The analyst cautions that outcomes from such analyses often fail to replicate in later studies. Bicycle Therapeutics plunges 30% to $14.07.  (katherine.hamilton@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 13, 2024 13:19 ET (18:19 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCYC","symbol_name":"Bicycle Therapeutics Limited","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2491309899","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491309899","pubTimestamp":1734113940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1319 ET - Bicycle Therapeutics takes a beating after sharing its latest cancer treatment trial results. B. Riley analyst Kalpit Patel says the results for Bicycle's zelenectide pevedotin therapy in conjunction with Merck's pembrolizumab to treat bladder cancer included \"a significant proportion of unconfirmed responses,\" and while the data are early, he says the effectiveness appears to be \"somewhat underwhelming,\" when compared to the established combination of Astellas' Padcev + pembro. Patel also says results for Bicycle's breast and lung cancer treatment relied on a post-hoc analysis, which carries \"an inherent risk of data mining.\" The analyst cautions that outcomes from such analyses often fail to replicate in later studies. Bicycle Therapeutics plunges 30% to $14.07.  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCYC":"Bicycle Therapeutics Limited","BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"Bicycle Therapeutics最新试验结果引发质疑——Market Talk","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCYC":0.9,"LENZ":1},"content_text":"1319 ET - Bicycle Therapeutics takes a beating after sharing its latest cancer treatment trial results. B. Riley analyst Kalpit Patel says the results for Bicycle's zelenectide pevedotin therapy in conjunction with Merck's pembrolizumab to treat bladder cancer included \"a significant proportion of unconfirmed responses,\" and while the data are early, he says the effectiveness appears to be \"somewhat underwhelming,\" when compared to the established combination of Astellas' Padcev + pembro. Patel also says results for Bicycle's breast and lung cancer treatment relied on a post-hoc analysis, which carries \"an inherent risk of data mining.\" The analyst cautions that outcomes from such analyses often fail to replicate in later studies. Bicycle Therapeutics plunges 30% to $14.07.  (katherine.hamilton@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  December 13, 2024 13:19 ET (18:19 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}